The Role of Gene Therapy in Premature Ovarian Insufficiency Management
AbstractPremature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before the age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g.; anticancer treatment, genetic disorders, and enzymatic defects) could be identified. Although hormone-replacement therapy, the principal therapeutic approach for POI, helps alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, an effective approach to manage patients with POI is highly warranted. Several mechanisms associated with POI have been identified, including the lack of function of the follicle-stimulating hormone (FSH) receptor, alterations in apoptosis control, mutations in Sal-like 4 genes, and thymulin or basonuclin-1 deficiency. The above mentioned may be good targets for gene therapy in order to correct defects leading to POI. The goal of this review is to summarize current experiences on POI studies that employed gene therapy, and to discuss possible future directions in this field. View Full-Text
Share & Cite This Article
Atabiekov, I.; Hobeika, E.; Sheikh, U.; El Andaloussi, A.; Al-Hendy, A. The Role of Gene Therapy in Premature Ovarian Insufficiency Management. Biomedicines 2018, 6, 102.
Atabiekov I, Hobeika E, Sheikh U, El Andaloussi A, Al-Hendy A. The Role of Gene Therapy in Premature Ovarian Insufficiency Management. Biomedicines. 2018; 6(4):102.Chicago/Turabian Style
Atabiekov, Ihor; Hobeika, Elie; Sheikh, Ujalla; El Andaloussi, Abdeljabar; Al-Hendy, Ayman. 2018. "The Role of Gene Therapy in Premature Ovarian Insufficiency Management." Biomedicines 6, no. 4: 102.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.